In this study, dermaseptin-PD-2 showed a broader activity spectrum than dermaseptin-PD-1 on the human cancer cell lines and both of them exhibited low cytotoxicity on normal human cells, which makes dermaseptins more promising candidates in the discovery of new anticancer drugs. Here, PAF1 is linked to cancer.